EP3655441A1 - Asprv1 als neutrophilenspezifischer marker und therapeutisches target für entzündliche erkrankungen - Google Patents

Asprv1 als neutrophilenspezifischer marker und therapeutisches target für entzündliche erkrankungen

Info

Publication number
EP3655441A1
EP3655441A1 EP18836128.1A EP18836128A EP3655441A1 EP 3655441 A1 EP3655441 A1 EP 3655441A1 EP 18836128 A EP18836128 A EP 18836128A EP 3655441 A1 EP3655441 A1 EP 3655441A1
Authority
EP
European Patent Office
Prior art keywords
asprvl
neutrophils
antibody
fragment
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18836128.1A
Other languages
English (en)
French (fr)
Other versions
EP3655441A4 (de
Inventor
Luc VALLIERES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Publication of EP3655441A1 publication Critical patent/EP3655441A1/de
Publication of EP3655441A4 publication Critical patent/EP3655441A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Definitions

  • ASPRVl is required for the chronic phase of EAE induced with a B cell-dependent myelin antigen (bMOG), but not for initial neutrophil recruitment or T cell priming, a, Kaplan-Meier plot of EAE incidence in wild-type (ASPRV1 +/+ ) and ASPRVl-deficient mice (ASPRVl -7- ) after immunization with either MOG35-55 or bMOG. Shaded area represents the 95% pointwise confidence interval. For sample size and statistical testing, see incidence in c. b, Severity of EAE over time by group versus time from appearance of first symptoms. P-value shown on graph was calculated by two-way ANOVA with repeated measures using rank-transformed scores.
  • binding fragments encompassed within the term "antigen-binding fragment" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V H and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR), e.g., VH CDR3.
  • CDR complementarity determining region
  • a “detectable moiety” is a moiety detectable by spectroscopic, photochemical, biochemical, immunochemical, enzymatic, chemical and/or other physical means.
  • a detectable moiety may be coupled either directly and/or indirectly (for example via a linkage, such as, without limitation, a DOTA or NHS linkage) to antibodies and antigen-binding fragments thereof of the present invention using methods well known in the art.
  • a wide variety of detectable moieties may be used, with the choice depending on the sensitivity required, ease of conjugation, stability requirements and available instrumentation.
  • ASPRVl protein is an aspartic peptidase
  • ASPRVl protein expressed in stratified epithelia cleaves profilaggrin. It is therefore possible that the ASPRVl protein expressed in neutrophils be also capable of processing profilaggrin and other substrats even if they may not be relevant for the neutrophil activity or phenotype.
  • the ASPRVl protein or fragment thereof may also be detected by peptide sequencing or other methods known to a person skilled in the art.
  • ICAMl was detected on capillaries, but not on intravascular neutrophils that exhibited the rod-shaped morphology typical of crawling leukocytes 22 (Figure 2c). In contrast, ICAMl was detected on the vast majority (> 90%) of extravascular neutrophils in the meninges and parenchyma ( Figure 2d). Neutrophils were also observed in the vasculature of naive and sham-treated mice (where they were negative for ICAMl), but never in the parenchyma, as previously reported 18,19 .
  • Ly6G + neutrophils Approximately 80% of all Ly6G + neutrophils from the spinal cord of EAE mice expressed ZsGreen. Curiously, Ly6G + neutrophils accounted for 78% of the ZsGreen + population, while the remaining 22% were other myeloid phagocytes: DCs, macrophages and microglia (Figure 5d).
  • ASPRVl mRNA was abundant in blood neutrophils in the steady state, but not in B cells, Th cells, monocytes or unfractionated mononuclear cells (Figure 7e). Further, ASPRVl mRNA was detected in higher amounts in brain lesions from patients with severe MS compared to both normal-appearing white matter and brain lesions from patients with typical forms of MS ( Figure 7f). Therefore, our results demonstrate that ASPRV1 is a neutrophil-specific protein in the immune system and can serve as a neutrophil marker in the nervous system both in the mouse and human.
  • ICAM1 facilitates cell-cell interactions such as the formation of immunological synapses 29 .
  • neutrophils act, at least in part, in a contact-dependent manner in demyelination, and provide a surface marker for the study of neutrophil subpopulations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
EP18836128.1A 2017-07-17 2018-07-09 Asprv1 als neutrophilenspezifischer marker und therapeutisches target für entzündliche erkrankungen Withdrawn EP3655441A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533398P 2017-07-17 2017-07-17
PCT/CA2018/000140 WO2019014744A1 (en) 2017-07-17 2018-07-09 ASPRV1 AS A NEUTROPHIL SPECIFIC MARKER AND THERAPEUTIC TARGET FOR INFLAMMATORY DISEASES

Publications (2)

Publication Number Publication Date
EP3655441A1 true EP3655441A1 (de) 2020-05-27
EP3655441A4 EP3655441A4 (de) 2021-06-30

Family

ID=65014907

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18836128.1A Withdrawn EP3655441A4 (de) 2017-07-17 2018-07-09 Asprv1 als neutrophilenspezifischer marker und therapeutisches target für entzündliche erkrankungen

Country Status (4)

Country Link
US (1) US20200355684A1 (de)
EP (1) EP3655441A4 (de)
CA (1) CA3067363A1 (de)
WO (1) WO2019014744A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221322A1 (en) * 2021-04-12 2022-10-20 Zelosdx, Inc. Detection of debris in recirculating phagocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
EP2185592B1 (de) * 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoklonaler amyloid-beta (abeta)-spezifischer antikörper und seine verwendung

Also Published As

Publication number Publication date
CA3067363A1 (en) 2019-01-24
EP3655441A4 (de) 2021-06-30
WO2019014744A1 (en) 2019-01-24
US20200355684A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
US11708412B2 (en) Methods for treating hematologic cancers
JP6527565B2 (ja) 脱毛障害を処置するための方法
EP3362074B1 (de) Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
Hawkins et al. ICAM1+ neutrophils promote chronic inflammation via ASPRV1 in B cell–dependent autoimmune encephalomyelitis
KR102223464B1 (ko) Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
US10066014B2 (en) Anti CD84 antibodies, compositions comprising same and uses thereof
KR20140054238A (ko) 인테그린 알파-v 베타-8에 결합하는 항체
KR20220042056A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-siglec-9 조성물 및 방법, 그리고 이의 용도
US20150315552A1 (en) Inhibition of AXL Signaling in Primary Tumor Therapy
KR20230066048A (ko) 심근경색증 치료를 위한 치료 방법 및 제제
JP4864278B2 (ja) 脱髄疾患を処置する方法
US20200355684A1 (en) Asprv1 as a neutrophil-specific marker and therapeutic target for inflammatory diseases
WO2018165015A1 (en) Treatment of pediatric brain tumors with targeting of cd47 pathway
WO2021101966A1 (en) Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
KR20220042131A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-lrrc25 조성물 및 방법, 그리고 이의 용도
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
WO2021127008A1 (en) Compositions and methods for treating neuromuscular disorders
CN115372611B (zh) Cd16+成纤维细胞在诊断、预防和治疗单克隆抗体耐药乳腺癌中的应用
WO2024173874A2 (en) Lair-1 agonistic antibodies and methods of use thereof
JPWO2020017629A1 (ja) Ｈｔｌｖ−１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
WO2022187660A1 (en) Compositions for and methods of preventing metastases
Rashighi et al. CXCL10, an IFN-γ-induced chemokine, is required for the development of depigmentation in a mouse model of vitiligo
Ferrer Immunomodulation in Transplantation: Promoting Tolerance and Protective Immunity
AU2007201935A1 (en) Methods for treating demyelinating disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/37 20060101ALI20210223BHEP

Ipc: G01N 33/48 20060101ALI20210223BHEP

Ipc: A61K 31/496 20060101ALI20210223BHEP

Ipc: C12Q 1/68 20180101ALI20210223BHEP

Ipc: C12Q 1/6876 20180101ALI20210223BHEP

Ipc: C07D 401/06 20060101ALI20210223BHEP

Ipc: A61P 29/00 20060101ALI20210223BHEP

Ipc: A61K 31/713 20060101ALI20210223BHEP

Ipc: A61K 39/395 20060101ALI20210223BHEP

Ipc: A61P 37/06 20060101ALI20210223BHEP

Ipc: A61P 25/28 20060101ALI20210223BHEP

Ipc: A61K 31/7088 20060101ALI20210223BHEP

Ipc: A61K 47/68 20170101ALI20210223BHEP

Ipc: C07K 16/40 20060101AFI20210223BHEP

Ipc: G01N 33/573 20060101ALI20210223BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210531

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/40 20060101AFI20210525BHEP

Ipc: A61K 31/496 20060101ALI20210525BHEP

Ipc: A61K 31/7088 20060101ALI20210525BHEP

Ipc: A61K 31/713 20060101ALI20210525BHEP

Ipc: A61K 39/395 20060101ALI20210525BHEP

Ipc: A61K 47/68 20170101ALI20210525BHEP

Ipc: A61P 25/28 20060101ALI20210525BHEP

Ipc: A61P 29/00 20060101ALI20210525BHEP

Ipc: A61P 37/06 20060101ALI20210525BHEP

Ipc: C07D 401/06 20060101ALI20210525BHEP

Ipc: C12Q 1/37 20060101ALI20210525BHEP

Ipc: C12Q 1/68 20180101ALI20210525BHEP

Ipc: C12Q 1/6876 20180101ALI20210525BHEP

Ipc: G01N 33/48 20060101ALI20210525BHEP

Ipc: G01N 33/573 20060101ALI20210525BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240201